The Chlamydia rapid test is a convenient immunochromatographic assay for the qualitative detection of Chlamydia trachomatis (C. trachomatis) antigen from urethral/genital swab specimens. It is intended for professional use as an aid in the diagnosis of C. trachomatis infection.
Chlamydia is a common sexually transmitted disease that can cause permanent damage to a women’s reproductive system, making pregnancy more difficult and more dangerous. Pregnant women with chlamydia hold a higher risk for birth complications. These include miscarriage, premature birth, and stillbirth. The disease can also be transmitted vertically during birth. Treatment for chlamydia is approved in pregnant women, and treatment before delivery erases the risk of transmission.
The CDC recommends testing for sexually active women under 25, older women with risk factors such as new or multiple partners, and every pregnant woman at their first prenatal visit.
The Chlamydia rapid test can be deployed in Asia, Latin America, Africa, Europe and Canada, but not yet in the U.S.
Please note: Order minimums of 500 Chlamidia rapid tests apply